BP Figure 4: Lack of effect of AZD1656 treatment on blood or liver triglyceride and cholesterol in P446L mice after 20 wk.

Experimental details were as in Figure-1. A) Blood triglycerides and cholesterol after 20 wk on HFHSD showing increased cholesterol (total and LDL) by LL genotype and by AZD1656 treatment in PP but not LL mice. B) Lack of effect of AZD1656 on liver triglyceride and cholesterol and liver enzymes (ALT, alanine aminotransferase; AST, aspartate aminotransferase) in plasma. Decrease in plasma inorganic phosphate by genotype but not by AZD1656. C) Lack of effect of AZD1656 on liver steatosis and fibrosis scores in PP and LL mice. *P < 0.05 effect of AZD1656; #P < 0.05 effect of genotype.

实验细节与图1一致。A) 小鼠在高脂高糖饮食（HFHSD）饲养20周后，其血液甘油三酯和胆固醇水平显示：LL基因型以及AZD1656处理可使PP小鼠（而非LL小鼠）的胆固醇（总胆固醇和低密度脂蛋白胆固醇，LDL）升高。B) AZD1656对肝脏甘油三酯、胆固醇及血浆中肝脏酶（ALT，丙氨酸氨基转移酶；AST，天冬氨酸氨基转移酶）无显著影响。基因型可降低血浆无机磷酸盐水平，但AZD1656无此作用。C) AZD1656对PP和LL小鼠的肝脏脂肪变性及纤维化评分无显著影响。*P < 0.05表示AZD1656的效应；#P <0.05表示基因型的效应。